🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,42 USD

Máx. histórico

478,48

2 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,77%

Rango 52 semanas

312,39 – 483,99

Variación hoy

+0,03%

Cierre anterior

460,28

Rango de hoy

447,04 – 462,91

Volumen hoy

2.578.799

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,69 (puede no estar actualizado)
Dividend yield
2,19% (puede no estar actualizado)
Precio objetivo analistas
409,63 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 11 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
20/02/2013 84,37 85,34 84,24 84,65 +0,62% 1,30% 6.388.300
19/02/2013 83,51 84,27 82,92 84,13 +0,62% 1,62% 5.944.300
15/02/2013 84,24 84,72 83,32 83,61 -1,31% 1,66% 5.622.200
14/02/2013 86,00 86,40 84,61 84,72 -0,26% 2,08% 6.189.100
13/02/2013 84,96 85,13 84,45 84,94 +0,47% 0,80% 7.943.200
12/02/2013 85,00 85,23 84,28 84,54 -0,45% 1,12% 4.656.000
11/02/2013 85,48 85,98 84,59 84,92 -2,13% 1,63% 7.538.400
08/02/2013 85,61 87,17 85,39 86,77 +1,82% 2,08% 8.354.900
07/02/2013 87,00 87,00 85,04 85,22 -1,58% 2,25% 7.639.700
06/02/2013 86,46 87,47 86,00 86,59 +0,07% 1,70% 5.549.100
05/02/2013 86,08 86,59 85,42 86,53 +0,92% 1,36% 4.577.900
04/02/2013 85,44 86,24 85,44 85,74 -0,65% 0,94% 3.907.500
01/02/2013 86,17 86,93 85,25 86,30 +0,98% 1,95% 3.379.500
31/01/2013 85,09 86,12 85,04 85,46 +0,09% 1,27% 4.269.700
30/01/2013 86,60 86,82 85,20 85,38 -1,40% 1,87% 4.963.100
29/01/2013 85,00 87,89 85,00 86,59 +1,17% 3,40% 21.502.900
28/01/2013 83,21 86,10 82,82 85,59 +2,60% 3,94% 9.426.900
25/01/2013 82,73 83,43 82,09 83,42 +0,97% 1,62% 7.235.200
24/01/2013 83,34 83,92 82,12 82,62 -0,54% 2,16% 8.071.300
23/01/2013 83,06 84,49 82,87 83,07 -0,26% 1,95% 7.670.400
22/01/2013 82,00 83,41 81,56 83,29 +1,47% 2,26% 9.394.900
18/01/2013 83,81 83,87 81,58 82,08 -2,22% 2,73% 14.408.700
17/01/2013 84,10 84,47 83,88 83,94 -0,45% 0,70% 6.268.400
16/01/2013 85,03 85,34 84,27 84,32 -0,89% 1,26% 7.753.800
15/01/2013 86,56 86,86 85,00 85,08 -2,12% 2,15% 6.277.900
14/01/2013 87,17 87,25 86,50 86,92 -0,05% 0,86% 4.401.000
11/01/2013 87,95 88,05 86,87 86,96 -0,97% 1,34% 4.681.700
10/01/2013 88,32 89,00 87,27 87,81 -0,97% 1,96% 5.861.200
09/01/2013 88,34 88,92 88,21 88,67 +0,59% 0,80% 3.372.500
08/01/2013 88,44 88,68 87,44 88,15 -0,43% 1,40% 5.170.700